Trogarzo™ (ibalizumab-uiyk) injection was developed by Taiwan’s Zhongyu New Drugs and is marketed in the US by Taiwan’s TaiMed Biologics. As a "virus entry inhibitor," ibalizumab binds to CD4, the major HIV receptor on the surface of T cells, to prevent these cells from getting invaded by the virus. As the first anti-retroviral therapy with a new mechanism of action in more than a decade, ibalizumab has received FDA-approved groundbreaking therapies, qualifications for priority review, fast track qualifications, and orphan drug qualifications.
Source: China Bio news release, March 7, 2018
Request a quote for deeper information from